Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02293954 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 19, 2014
Last Update Posted : October 21, 2022
|
Sponsor:
City of Hope Medical Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may help find and diagnose CEA positive cancer that may not be detected by standard diagnostic methods.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer Colon Cancer Extrahepatic Bile Duct Cancer Gallbladder Cancer Gastrointestinal Cancer Liver and Intrahepatic Biliary Tract Cancer Lung Cancer Metastatic Cancer Pancreatic Cancer Rectal Cancer Thyroid Gland Medullary Carcinoma Unspecified Adult Solid Tumor, Protocol Specific | Procedure: radionuclide imaging Procedure: positron emission tomography Other: laboratory biomarker analysis Other: pharmacological study Drug: Cu 64 anti-CEA monoclonal antibody M5A IV | Not Applicable |
PRIMARY OBJECTIVES:
I. To determine the ability of 64Cu labeled M5A antibody (copper Cu 64 anti-CEA monoclonal antibody M5A) to localize CEA positive cancers (such as gastrointestinal, lung, medullary thyroid and breast cancers), as determined by PET imaging.
SECONDARY OBJECTIVES:
I. To characterize the frequency of titer of the human anti-human antibody (HAHA) response to 64Cu labeled M5A antibody.
II. To determine the safety of administration of 64Cu labeled M5A antibody.
OUTLINE:
Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A intravenously (IV) on day 0 and then undergo PET on day 1 and day 2.
After completion of study, patients are followed up at 1 and 3 months.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 20 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA) |
| Actual Study Start Date : | November 11, 2015 |
| Estimated Primary Completion Date : | September 11, 2023 |
| Estimated Study Completion Date : | September 11, 2023 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Globulin, Immune
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)
Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
|
Procedure: radionuclide imaging
Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
Other Name: radionuclide scanning Procedure: positron emission tomography Undergo PET
Other Names:
Other: laboratory biomarker analysis Correlative studies Other: pharmacological study Correlative studies
Other Name: pharmacological studies Drug: Cu 64 anti-CEA monoclonal antibody M5A IV Cu 64 anti-CEA monoclonal antibody M5A IV |
Primary Outcome Measures :
- Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using lesion analysis [ Time Frame: Up to day 2 ]For lesion analysis, the efficacy of each modality will be evaluated where a successful outcome will be defined as the ability of at least one known tumor identified by conventional imaging modalities to be imaged using the M5A antibody. Using the standard statistical formulas, the number of true positives, false positives, true negatives, and false negatives, as well as the sensitivity and corresponding 95% confidence interval will be estimated using the method of Lee and Dubin or Rao and Scott, which accounts for the correlation between lesions within in same subject.
- Efficacy of each modality in locating cancer in each of four regions (primary, hepatic, extra-hepatic abdominal, and extra-abdominal) using region analysis [ Time Frame: Up to day 2 ]For region analysis, a successful outcome will be defined as the identification of suspicious tissue within a region. Using the standard statistical formulas, the number of true positives, false positives, true negatives, and false negatives, as well as the sensitivity and corresponding 95% confidence interval will be estimated using the method of Lee and Dubin or Rao and Scott, which accounts for the correlation between lesions within in same subject.
- Pharmacokinetic parameters of copper Cu 64 anti-CEA monoclonal antibody M5A [ Time Frame: Pre-dose, 30 minutes, and 1, 2, and 3-4 hours post start of infusion ]Blood samples will be drawn at various time points to construct the blood activity curve. Urine data will also be included in our analyses to check the whole body clearance curves. A computer pharmacokinetic model containing 5 compartments including blood, liver, residual body, urine and feces will be used to analyze time activity data. Residence times for various organs will be calculated from this pharmacokinetic model and/or uptake data. Different residence times for different isotopes, e.g. 64Cu, will be calculated by adjusting for physical decay. These times are then substituted into the OLINDA program.
- Immunogenicity properties of copper Cu 64 anti-CEA monoclonal antibody M5A [ Time Frame: Up to 3 months ]The patient's serum samples are evaluated in both a bridging radioimmunoassay and an HPLC assay. The sera are incubated with the appropriate radiolabeled M5A and then analyzed by HPLC size exclusion chromatography on a Superose 6 HR column.
Secondary Outcome Measures :
- Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [ Time Frame: Up to 3 months ]Safety data will be displayed and abnormal laboratory values flagged. The frequency of adverse events will be tabulated by body system.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have histologically confirmed primary or metastatic cancer; if biopsies were performed at an outside facility, the histology must be reviewed and confirmed by the Department of Pathology at the City of Hope
- Patients must have tumors that produce CEA as documented by a current or past history of an elevated serum CEA above the institutional limit of normal, or by immunohistochemical methods; NOTE: Patients with colorectal cancer are exempt from this requirement since > 95% are CEA positive
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
- Patients must have a known site of disease; please note, for patients undergoing neoadjuvant therapy, this requirement must be met retrospectively prior to the start of neoadjuvant therapy; patients who are in radiological/clinical remission after neoadjuvant therapy, prior to infusion of radiolabeled antibody, are still eligible
- Although not mandated by the protocol, the results of the CT scan and labs (complete blood count [CBC], comprehensive metabolic panel [CMP]) that are performed as part of the standard work up should be available and should have been done within 2 months prior to study entry
- All subjects must have the ability to understand and the willingness to sign a written informed consent
- Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 2 weeks prior to infusion of radiolabeled antibody
Exclusion Criteria:
- Patients should not have any uncontrolled illness including ongoing or active infection
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu 64 anti-CEA monoclonal antibody M5A (64Cu-M5A)
- Patients must not have received prior chemotherapy or radiation for >= 2 weeks before study enrollment
- Pregnant women are excluded from this study; breastfeeding should be discontinued is the mother is treated with 54Cu-m5A
- Any patient who has had exposure to mouse or chimeric (human/mouse) immunoglobulin and has antibody to the M5A
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02293954
Locations
| United States, California | |
| City of Hope Medical Center | |
| Duarte, California, United States, 91010 | |
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Jeffrey Wong | City of Hope Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | City of Hope Medical Center |
| ClinicalTrials.gov Identifier: | NCT02293954 |
| Other Study ID Numbers: |
14238 NCI-2014-02079 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 14238 ( Other Identifier: City of Hope Medical Center ) |
| First Posted: | November 19, 2014 Key Record Dates |
| Last Update Posted: | October 21, 2022 |
| Last Verified: | October 2022 |
Additional relevant MeSH terms:
|
Carcinoma Biliary Tract Neoplasms Gastrointestinal Neoplasms Gallbladder Neoplasms Bile Duct Neoplasms Carcinoma, Medullary Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Biliary Tract Diseases |
Gallbladder Diseases Bile Duct Diseases Adenocarcinoma Carcinoma, Neuroendocrine Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Nerve Tissue Antibodies Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs |